...will remain in her role as CBO. Byrnes previously served as SVP of finance at Principia Biopharma...

...is transitioning to a new role in venture capital. Thomas was most recently CMO at Principia Biopharma...

...hired Pasit Phiasivongsa as SVP of pharmaceutical development. Phiasivongsa was most recently SVP, technical operations, at Principia Biopharma...

...biotechs, such as CRISPR Therapeutics AG (NASDAQ:CRSP); Principia Biopharma Inc....

...SAR442168, which Sanofi (Euronext:SAN; NASDAQ:SNY) acquired full rights to through its $3.4 billion takeout of Principia Biopharma Inc....

...outcome for Principia,” wrote Lampert. “We are open to discussing our views with any interested parties.”Principia Biopharma Inc....

...could yield further candidates and effectively buys out its own milestone and royalty obligations to Principia Biopharma Inc....
...for an overview of other therapies in development for MS. TARGETSBtk – Bruton’s tyrosine kinase Paul Bonanos PRN2246, SAR442168 Sanofi Principia Biopharma Inc. Bruton's...

...NR-SPMS are on track to begin mid-year. Sanofi licensed the Btk inhibitor in 2017 from Principia Biopharma Inc....
...a market cap of $2.1 billion. Targets Btk - Bruton’s tyrosine kinase Sandi Wong, Assistant Editor PRN2246, SAR442168 Sanofi Principia Biopharma Inc. Bruton's...

...assessed by MRI. Sanofi has global development and commercial rights to the BTK inhibitor from Principia Biopharma Inc....
...BTK - Bruton’s tyrosine kinase BioCentury Staff PRN2246, SAR442168 Flanders Institute for Biotechnology (VIB) Ghent University NIH University of Texas at Austin Sanofi Principia Biopharma Inc. Coronavirus...

...build on its success in multiple sclerosis with BTK inhibitor SAR442168, which is licensed from Principia Biopharma Inc....